Skip to the lineages
Regenerative Medicine

What Does Cell Viability Mean for Injectable Cell Products?

Published November 16, 2026

Protocol: 7 steps in this guide
  1. Live/dead tests in plain language
  2. Viability percentage versus the dose of living cells
  3. Timing and handling after collection
  4. Potency and the intended mechanism
  5. Identity and contamination checks
  6. Batch consistency
  7. Why clinical efficacy is a separate question

Cell viability is the share of cells in a sample that are alive when they are tested. It is one quality measure among several. A high viability figure does not tell you how many living cells you will receive, whether they are the type of cell claimed, whether they can do what is promised, or whether the product is free of contamination, and it says nothing about whether the treatment works. Laboratory tests of some marketed cord-tissue products have found viability between 0% and 22%, while an approved cell product is defined by a fixed cell dose, handling rules and a stated indication.

Live/dead tests in plain language

A viability test counts cells and sorts them into living and dead. Published product studies show what this looks like in practice. A 2021 laboratory study in the American Journal of Sports Medicine (Berger and colleagues) used image-based methods to measure cell concentration and viability in five commercial umbilical cord products. A 2026 review in the Journal of Translational Medicine, Critical evaluation of compositions and clinical relevance of Wharton’s jelly-derived biologics, microscopically counted total cells and viable cells in Wharton’s jelly products and reported 0 to 19.1% viability.

Viability percentage versus the dose of living cells

A percentage is a ratio, so it needs a count beside it. As an illustrative calculation, not data from any product:

  • Suppose product A contains 100,000 cells at 90% viability: 100,000 × 0.90 = 90,000 living cells.
  • Suppose product B contains 10,000,000 cells at 20% viability: 10,000,000 × 0.20 = 2,000,000 living cells.

Product A has the better percentage; product B delivers about 22 times as many living cells. Neither number, on its own, shows benefit. An approved product states its dose as a cell count. FDA’s prescribing information for Ryoncil, an approved donor bone marrow-derived stromal cell product, states that each cryovial contains nominally 25 million MSCs in 3.8 mL, and that the product is dosed by body weight, at 2 million MSCs per kilogram in the clinical study. The product’s FDA listing is on its Ryoncil product page.

Timing and handling after collection

Viability is measured at a point in time, and the result describes the cells at that moment, not at the moment of injection. Handling rules exist for this reason. Ryoncil’s prescribing information states that it must remain frozen at or below -135°C in the vapor phase of liquid nitrogen until it is thawed immediately before administration, and that preparation should follow aseptic technique in a biological safety cabinet. When a clinic reports viability, ask when and where it was measured: at manufacture, at release, or just before injection.

Potency and the intended mechanism

Potency is whether the cells can do the specific job the product is supposed to do. A 2026 study in Frontiers in Immunology, Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells, states that “variability in clinical efficacy and a lack of validated potency assays have impeded regulatory approval for commercialization” of MSC therapies. The authors built a set of laboratory tests, such as suppression of T-cell proliferation and shifting of immune cells toward an anti-inflammatory state, to check that each batch behaves as expected; the authors were employees of Ossium Health, Inc., as the paper discloses. Even for an approved product, the mechanism may be uncertain: Ryoncil’s label states that its mechanism of action “is not clear but may be related to immunomodulatory effects.”

Identity and contamination checks

Living cells may still be the wrong cells. Identity testing, for example by surface markers, checks that the cells are what the label says; the criteria for stromal cells are covered in what mesenchymal stromal cells are, and marker-based identification in how Muse cells are identified in laboratory samples. Sterility testing checks for bacteria and other microbes; a product can be highly viable and contaminated. Donor-derived products also raise immune questions, covered in the risks of immune reactions to donor-derived cell products.

Batch consistency

One good test result describes one sample. The Frontiers in Immunology study’s purpose was to show consistent function across donors and manufactured lots, reporting that its tests “consistently demonstrated predicted in vitro functionality of MSCs derived from 10 donors.” A clinic that cannot show results for the batch being injected is relying on someone else’s sample.

A blank quality record shows the fields worth asking about. It is a template, not a real certificate:

Attribute What it answers Result for this batch
Identity Are these the cells claimed?
Total cell count How many cells are in the dose?
Viability (and when measured) What share are alive?
Viable cell dose How many living cells will be given?
Potency Can the cells do the intended job in a test?
Sterility Is the product free of microbial contamination?
Expiration or use-by time How long is the product good after thaw or preparation?

Why clinical efficacy is a separate question

Every attribute above is a laboratory measure. Whether a product helps a condition is answered only by clinical trials of that product for that condition. For cell products promoted for joints, that question is covered in what clinical trials show about stem cell injections for knee osteoarthritis, and claims about Wharton’s jelly products in what Wharton’s jelly is and why it is marketed for joint injections.

Cell viability tells you what share of cells were alive when tested, but a useful quality claim also needs the total and viable cell dose, identity, potency, sterility and timing, and even a complete quality record does not show that an injection works.

Cells linked to this one

This guide leads on to

Guides that lead here

Lineage E: Stem Cell Sources and Products

What readers added

Add a remark

Your email address will not be published. Required fields are marked *